[go: up one dir, main page]

ATE433106T1 - Bestimmungsmethode fur liganden der nuklearen rezeptoren - Google Patents

Bestimmungsmethode fur liganden der nuklearen rezeptoren

Info

Publication number
ATE433106T1
ATE433106T1 AT99967639T AT99967639T ATE433106T1 AT E433106 T1 ATE433106 T1 AT E433106T1 AT 99967639 T AT99967639 T AT 99967639T AT 99967639 T AT99967639 T AT 99967639T AT E433106 T1 ATE433106 T1 AT E433106T1
Authority
AT
Austria
Prior art keywords
ligands
nuclear receptors
determination method
nuclear
nuclear receptor
Prior art date
Application number
AT99967639T
Other languages
English (en)
Inventor
Steven Gerard Blanchard
Steven Anthony Kliewer
Jurgen Lehmann
Derek J Parks
Julie Beth Stimmel
Timothy Mark Willson
Curt Dare Haffner
Patrick Reed Maloney
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE433106T1 publication Critical patent/ATE433106T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99967639T 1998-12-23 1999-12-22 Bestimmungsmethode fur liganden der nuklearen rezeptoren ATE433106T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13509798P 1998-12-23 1998-12-23
PCT/US1999/030947 WO2000037077A1 (en) 1998-12-23 1999-12-22 Assays for ligands for nuclear receptors

Publications (1)

Publication Number Publication Date
ATE433106T1 true ATE433106T1 (de) 2009-06-15

Family

ID=22466527

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99967639T ATE433106T1 (de) 1998-12-23 1999-12-22 Bestimmungsmethode fur liganden der nuklearen rezeptoren

Country Status (9)

Country Link
US (2) US6639078B1 (de)
EP (1) EP1140079B1 (de)
JP (1) JP2002532729A (de)
AT (1) ATE433106T1 (de)
AU (1) AU2389100A (de)
CA (1) CA2356887A1 (de)
DE (1) DE69940958D1 (de)
ES (1) ES2326850T3 (de)
WO (1) WO2000037077A1 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238491B1 (en) 1998-03-27 2007-07-03 Smithkline Beecham Corporation Pregnane X receptor method
CN1187364C (zh) * 1999-04-30 2005-02-02 亚其发展公司 类固醇衍生物
AU2001288623A1 (en) * 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
JP4593754B2 (ja) * 2000-10-13 2010-12-08 一般財団法人 化学物質評価研究機構 化学物質の５０％阻害濃度決定方法
WO2002062302A2 (en) * 2001-02-08 2002-08-15 The University Of Chicago Steroidal derivatives
US20020119958A1 (en) * 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
IL157816A0 (en) 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
WO2002090375A2 (en) * 2001-05-03 2002-11-14 The University Of Chicago Liver x receptor agonists
US20070197484A1 (en) * 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
DE60131967D1 (de) * 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
CA2469435A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
ES2367539T3 (es) 2001-12-21 2011-11-04 X-Ceptor Therapeutics, Inc. Moduladores heterocíclicos de receptores nucleares.
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003080803A2 (en) * 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
WO2003086303A2 (en) * 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US7319109B2 (en) 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
US7302347B2 (en) * 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
ES2361924T3 (es) 2002-12-20 2011-06-24 X-Ceptor Therapeutics, Inc. Derivados de isoquinolinona y su uso como agentes terapéuticos.
US20070015796A1 (en) * 2003-09-26 2007-01-18 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
PT1734970E (pt) * 2004-03-12 2015-03-11 Intercept Pharmaceuticals Inc Tratamento de fibrose utilizando ligandos de rfx
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
KR100704011B1 (ko) * 2005-02-16 2007-04-04 한국과학기술원 금속나노입자와 양자점의 ｆｒｅｔ에 의한 생체분자특이결합 검출 방법
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP5237799B2 (ja) 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのｌｘｒモジュレーター
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
ES2374165T3 (es) 2005-12-19 2012-02-14 Glaxosmithkline Llc Agonistas del receptor x farnesoide.
US7932244B2 (en) 2006-06-27 2011-04-26 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
EA017714B1 (ru) 2007-01-19 2013-02-28 Интерсепт Фармасьютикалз, Инк. Модуляторы tgr5 и способы их применения
US9006283B2 (en) 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
US8962677B2 (en) * 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US20110098309A1 (en) * 2007-07-12 2011-04-28 Acumen Pharmaceuticals, Inc. Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
WO2009079566A2 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
EP2108706A1 (de) 2008-04-10 2009-10-14 Institut Pasteur Neues Verfahren zum Auswählen von Verbindungen, die zur Behandlung und/oder Prävention von mikrobiellen Infektionen mit Shigella sinnvoll sind
EP2128158A1 (de) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclische Cyclopropyl-substituierte FXR-bindende Verbindungen
EA020310B1 (ru) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
AU2009316566B9 (en) 2008-11-19 2014-05-15 Intercept Pharmaceuticals, Inc. TGR5 modulators and method of use thereof
WO2010069604A1 (en) * 2008-12-19 2010-06-24 Royal College Of Surgeons In Ireland Treatment of diarrhoea
ES2620451T3 (es) 2009-05-28 2017-06-28 Exelixis Patent Company Llc Moduladores de los LXR
CA2769203A1 (en) * 2009-07-29 2011-02-03 University Of Chicago Liver x receptor agonists
EP2289883A1 (de) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Neue Aktivitätsmodulationsverbindungen für FXR- (NR1H4)
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
IL253437A0 (en) * 2011-07-13 2017-09-28 Gilead Sciences Inc New compounds modulate fxr (nr1h4) activity and bind
EP2545964A1 (de) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
CA2876706A1 (en) 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
KR20190121871A (ko) 2012-06-19 2019-10-28 인터셉트 파마슈티컬즈, 인크. 오베티콜산의 제조법, 용도 및 고체 형태
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
CN105209039B (zh) 2013-03-15 2018-06-22 百时美施贵宝公司 Lxr调节剂
CN108245523B (zh) 2013-05-14 2021-03-26 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11-羟基衍生物及其氨基酸共轭物
CN110437297B9 (zh) * 2013-08-01 2022-01-11 美国卫生和人力服务部 法尼醇x受体的抑制剂和在医学中的用途
PL3043865T3 (pl) 2013-09-11 2021-07-05 Institut National De La Santé Et De La Recherche Médicale (Inserm) SPOSOBY I KOMPOZYCjE FARMACEUTYCZNE W LECZENIU ZAKAŻENIA WIRUSEM ZAPALENIA WĄTROBY TYPU B
CN104513213A (zh) * 2013-09-28 2015-04-15 山东亨利医药科技有限责任公司 Fxr激动剂
LT3626725T (lt) * 2014-05-29 2023-03-10 Bar Pharmaceuticals S.R.L. Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai
EP3006939A1 (de) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidinreiches Glycoprotein als Marker zur hepatischen Farnesoid-X-Aktivierung
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MX2017006833A (es) 2014-11-26 2018-02-13 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
EP3034499A1 (de) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Neuartige FXR (NR1H4) modulierende Verbindungen
EP3034501A1 (de) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxyhaltige FXR (NR1H4) modulierende Verbindungen
DK3253382T3 (da) 2015-02-06 2022-02-14 Intercept Pharmaceuticals Inc Farmaceutiske sammensætninger til kombinationsterapi
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
US20160271149A1 (en) * 2015-03-16 2016-09-22 Epinova Therapeutics Corp. Therapeutic compounds that suppress protein arginine methyltransferase activity for reducing tumor cell proliferation
SMT202100593T1 (it) 2015-03-31 2021-11-12 Enanta Pharm Inc Derivati degli acidi biliari come agonisti di fxr/tgr5 e metodi per il loro uso
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
SG11201806348PA (en) 2016-01-28 2018-08-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Steroid derivative fxr agonist
CN107021957A (zh) * 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
MX2018015443A (es) 2016-06-13 2019-04-11 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
CA3039124A1 (en) 2016-10-04 2018-04-12 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
CA3045023A1 (en) 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
AU2018243719B2 (en) 2017-03-28 2021-01-21 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
JP2020515564A (ja) 2017-03-30 2020-05-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物
AU2018249950B2 (en) 2017-04-07 2023-09-21 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
LT3612520T (lt) * 2017-04-12 2022-02-10 Il Dong Pharmaceutical Co., Ltd. Izoksazolo dariniai, kaip branduolio receptoriaus agonistai, ir jų panaudojimas
JP6997870B2 (ja) 2017-07-06 2022-02-10 シュアンチュー バイオファーマシューティカル カンパニー，リミティド Ｆｘｒ受容体刺激薬
EP3660030A4 (de) 2017-07-26 2021-04-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Verfahren zur herstellung von steroidderivat-fxr-agonisten
JP7244487B2 (ja) 2017-07-26 2023-03-22 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド ステロイド系誘導体ｆｘｒアゴニストの結晶又は非晶質、その製造方法及び使用
EP3704112B1 (de) 2017-11-01 2023-09-27 Bristol-Myers Squibb Company Alken-spirozyklische verbindungen als farnesoid-x-rezeptormodulatoren
WO2019089670A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Alkene compounds as farnesoid x receptor modulators
EP3704107B1 (de) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Multizyklische verbindungen als farnesoid-x-rezeptormodulatoren
WO2019085963A1 (zh) 2017-11-02 2019-05-09 正大天晴药业集团股份有限公司 一种胆酸类化合物的制备方法
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2019212946A1 (en) 2018-04-30 2019-11-07 Ribon Therapeutics Inc. Screening methods for parp modulators
CA3124702A1 (en) 2019-01-15 2020-07-23 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
SG11202113155XA (en) 2019-05-30 2021-12-30 Intercept Pharmaceuticals Inc Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
US20220227745A1 (en) * 2019-06-14 2022-07-21 Nanjing Ruijie Pharma Tech Co., Ltd. Compounds For Modulating FXR
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
CN110540955B (zh) * 2019-08-28 2021-09-17 北京协同创新研究院 一种提高分化细胞中nrob2基因表达量的方法
US20230060715A1 (en) 2020-01-15 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
CN117202905A (zh) 2021-01-14 2023-12-08 埃尼奥制药公司 Fxr激动剂和ifn用于治疗hbv感染的协同效果
EP4329761A1 (de) 2021-04-28 2024-03-06 ENYO Pharma Starke potenzierung von tlr3-agonisten-effekten mit fxr-agonisten als kombinierte behandlung
WO2023085931A1 (en) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatic organoids
WO2024005586A1 (ko) * 2022-06-30 2024-01-04 일동제약(주) 아이속사졸 유도체 또는 이의 염의 신규한 결정형

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE59813B1 (en) 1986-05-09 1994-04-06 Warner Lambert Co Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
WO1991015479A1 (en) 1990-03-30 1991-10-17 Merck & Co., Inc. Substituted pyrazoles, isoxazoles and isothiazoles
JPH0580530A (ja) * 1991-09-24 1993-04-02 Hitachi Ltd 薄膜パターン製造方法
US5900160A (en) * 1993-10-04 1999-05-04 President And Fellows Of Harvard College Methods of etching articles via microcontact printing
TW321731B (de) * 1994-07-27 1997-12-01 Hitachi Ltd
US6005086A (en) * 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
DE69626986T2 (de) 1995-08-02 2004-02-05 Smithkline Beecham Corp. Endothelinrezeptorantagonist
AU6774996A (en) * 1995-08-18 1997-03-12 President And Fellows Of Harvard College Self-assembled monolayer directed patterning of surfaces
US6162569A (en) * 1996-11-21 2000-12-19 Matsushita Electric Industrial Co., Ltd. Method for manufacturing fine pattern, and color filter, shading pattern filter and color LCD element formed and printed board by using the same
CA2305711A1 (en) 1997-10-07 1999-04-15 Merck & Co., Inc. Assays for nuclear receptor ligands using fret
US6410245B1 (en) * 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
JP2002528721A (ja) 1998-10-23 2002-09-03 グラクソ グループ リミテッド 核内受容体のリガンド用のアッセイ
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
DE60029029T2 (de) 1999-03-26 2007-06-14 City Of Hope, Duarte Screenen nach FXR-Rezeptormodulatoren
NL1016779C2 (nl) * 2000-12-02 2002-06-04 Cornelis Johannes Maria V Rijn Matrijs, werkwijze voor het vervaardigen van precisieproducten met behulp van een matrijs, alsmede precisieproducten, in het bijzonder microzeven en membraanfilters, vervaardigd met een dergelijke matrijs.
US6632536B2 (en) * 2000-12-28 2003-10-14 International Business Machines Corporation Self-assembled monolayer etch barrier for indium-tin-oxide useful in manufacturing thin film transistor-liquid crystal displays

Also Published As

Publication number Publication date
US6984650B2 (en) 2006-01-10
EP1140079A4 (de) 2004-06-09
EP1140079B1 (de) 2009-06-03
WO2000037077A1 (en) 2000-06-29
US20040048316A1 (en) 2004-03-11
US6639078B1 (en) 2003-10-28
JP2002532729A (ja) 2002-10-02
EP1140079A1 (de) 2001-10-10
AU2389100A (en) 2000-07-12
CA2356887A1 (en) 2000-06-29
DE69940958D1 (de) 2009-07-16
ES2326850T3 (es) 2009-10-20

Similar Documents

Publication Publication Date Title
DE69940958D1 (de) Bestimmungsmethode fur liganden der nuklearen rezeptoren
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
GB2318580B (en) Microspheres with fluorescent spherical zones
DE69227347D1 (de) Auf rezeptorgrundlage arbeitende screening-verfahren für amylin-agonisten und- antagonisten
DK0708922T3 (da) Identificering af ligander ved selektiv amplifikation af celler transfekteret med receptorer
AR059470A2 (es) Receptor para una proteina de la clase vip3 , secuencia de adn, anticuerpos, metodo para identificar y aislar homologos del receptor y metodo para identificar compuestos como ligandos quimicos del receptor vip3
ATE528648T1 (de) Verfahren zum nachweis antikörper-herstellender zellen
PT1015608E (pt) Metodos de ensaio de actividade de receptor e construcoes uteis nesses metodos
DE69901714D1 (de) Elektrochemischer affinitätsassay
AR017872A1 (es) Metodo para determinar la impedancia de adhesion de una entubacion circunferencial auto-calibrada.
KR950700414A (ko) 사람 인터루킨-4에 대한 사람화 모노클로날 항체의 클로닝 및 발현(Cloning and expression of humanized monoclonal antibodies against human interleukin-4)
DZ3147A1 (fr) Méthode de surveillance sismique d'une zone souterraine par utilisation simultanée de plusieurs sources vibrosismiques.
DK1734368T3 (da) Annexin-autoantistoffer anvendt som markörer for lungecancer
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
DK1137943T3 (da) Fremgangsmåde til påvisning af cancer og reagenser
ATE421584T1 (de) Cpg rezeptor (cpg-r) und darauf bezogene methoden
EP1082310A4 (de) Verfahren zur identifizierung und verwendung von an hla bindenden verbindungen als hla-agonisten und -antagonisten
ATE336721T1 (de) Hoch-durchsatz assay zur messung von zellulären antworten mit hilfe von mikroarrays
ES2190487T3 (es) Nuevos agonistas y antagonistas del receptor de adenosina a1.
CY1107621T1 (el) Μεθοδος ανιχνευσης αντισωματων σε ενα δειγμα
DE69837811D1 (de) Menschlicher lysophosphatidsäure rezeptor und dessen verwendung
DK0902286T3 (da) Immunanalyse med anvendelse af to inkubationer med mærket antigen
ES2168310T3 (es) Reactivos y metodos de deteccion y de cuantificacion de la testosterona en muestras de fluido.
DK1224222T3 (da) Chemokinreceptor
ES2112211A1 (es) Procedimiento para el estudio del ciclo celular de subpoblaciones de celulas presentes en muestras celulares heterogeneas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties